19 patients who developed significant neutropenia (neutrophils < 800/mm3) was treated with a flexibile scheme of 150–300 μg of G-CSF twice a week and matched with 19 neutropenic patients treated with IFN dose reduction/discontinuation as control group. This evidence concerns the gene CSF3 and neutropenia.